CROs call for better ways to leverage investigative site relationships

By Zachary Brennan contact

- Last updated on GMT

CROs are looking to do more to help investigative sites, which they rely on consistently.
CROs are looking to do more to help investigative sites, which they rely on consistently.

Related tags: Clinical research sites, Clinical trial, Contract research organization

Improving investigative site relationships in 2015 is a top priority for pharma and CRO (contract research organization) execs, according to a roundtable recently hosted by the Tufts Center for the Study of Drug Development.

Specifically, Tufts found that soliciting input from clinical research sites on protocol design, providing payments directly to study patients, sharing their development plans, and providing feedback via quality metric scorecards can help sponsors and CROs mitigate challenges.

Patient recruitment remains the largest challenge clinical research sites face, with more than half of sites saying sponsors and CROs they work with don’t provide sufficient information about the studies they’re working on.

Also posing a burden on sites is the way sponsors/CROs pay them. According to the Society for Clinical Research Sites (SCRS), in 2014 about 65% of clinical research sites had less than three months of operating cash -- a slight increase from 57% in 2012. On average, sites also pay for patient visits as a study rolls out, but the sites don’t typically receive pay­ment from sponsors/CROs until about five to six months after the work is completed.

And to help guard against unpredictable site performance, sponsors and CROs have reduced the average num­ber of randomized patients per trial expected of each engaged investigative site, according to Tufts, though this has resulted in an unintended consequence of limiting sites’ ability to operate efficiently.

Participants in the roundtable said they are looking to solicit more input from investigative sites to guide study planning and execution; incorporate anticipated changes in the site landscape, such as the integration of clinical research into patient care at large health institutions; and establish new relationship support mechanisms.

Tufts gives the example of having a medical monitor available 24/7 to answer questions when patients are at an active trial site can help sponsors and CROs ensure strong site performance.

New Paradigm

A CRO that conducts clinical trials globally also suggested to Tufts that strategic site relationships are creating a “new par­adigm​” in site management because strategic partnerships between sponsors and CROs are adding to CROs’ responsibility to select and manage sites.

Sites that want to build their business over the medium- to long-term are responding by adopting best practices, including better management of data and investing in their relationships with CROs​,” Tufts notes. From a CRO’s perspective, criteria that make a site suitable for a strategic relationship include:

-        The ability to solve problems quickly, provide effective protocol and technical training;

-        Ensure clinical trial materials and investigational drugs arrive at the site on time; and

-        Ensure that the clinical research associate is kept abreast of the protocol and therapeutic area.

Related news

Show more

Related products

show more

Laboratory Solutions for COVID-19 Clinical Trials

Laboratory Solutions for COVID-19 Clinical Trials

Q2 Solutions | 10-Jun-2020 | Clinical Study

As a leading laboratory services organization for trials across the globe, we are proud to partner with clients to support COVID-19 clinical trials. Our...

Parents as Gatekeepers for Children with Cancer

Parents as Gatekeepers for Children with Cancer

PRA Health Sciences | 08-Jun-2020 | Technical / White Paper

The RACE for Children Act will require new drugs intended for adult cancer treatment to also be studied in pediatric cancers when the molecular target...

RACE Act Prompts Pediatric Oncology Trials

RACE Act Prompts Pediatric Oncology Trials

PRA Health Sciences | 04-May-2020 | Technical / White Paper

Many providers prescribe drugs off-label to pediatric patients, even though there have been few pediatric trials for many of these drugs. In response,...

Manufacturing Cyto and Non-Cyto Drugs in One Facility

Manufacturing Cyto and Non-Cyto Drugs in One Facility

Baxter BioPharma Solutions | 01-Mar-2020 | Technical / White Paper

Recent market reports suggest increasing product niches, which may lead to decreasing numbers of units per product, making dedicated facilities less practical....

Related suppliers

Follow us


View more